Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mouwasat Medical Services CoSAU:4002 +0.25%100 EBITDA Margin % is 33.80% as of Mar. 2026, which is 3% below its 10-year median of 34.72. GuruFocus rates SAU:4002 with a GF Score™ of 100/100 and a GF Value™ of ﷼109.50 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Mouwasat Medical Services Co ranks better than 94.14% on this metric.
Mouwasat Medical Services Co (SAU:4002) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Mouwasat Medical Services Co EBITDA Margin % Related Terms
Mouwasat Medical Services Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mouwasat Medical Services Co EBITDA Margin % Chart
SAU:4002 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Mouwasat Medical Services Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mouwasat Medical Services Co EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mouwasat Medical Services Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Mouwasat Medical Services Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mouwasat Medical Services Co (SAU:4002) has a EBITDA Margin % of 33.80% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mouwasat Medical Services Co and its competitors. This is near median its historical median of 34.72. Over the past decade, Mouwasat Medical Services Co's EBITDA Margin % has ranged from 30.51 to 37.35. According to the industry distribution chart, Mouwasat Medical Services Co ranks #39 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 5.9%.
Is Mouwasat Medical Services Co's EBITDA Margin % too high?
Mouwasat Medical Services Co's current EBITDA Margin % of 33.80% is near median its 10-year median of 34.72. Over the past 10 years, this metric has ranged from a low of 30.51 to a high of 37.35. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Mouwasat Medical Services Co's value of 33.80% is 230.1% above this industry median. Based on the distribution chart, Mouwasat Medical Services Co ranks #39 out of 665 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mouwasat Medical Services Co has a GF Score™ of 100/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mouwasat Medical Services Co's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Mouwasat Medical Services Co ranks #39 out of 665 companies for EBITDA Margin %. This places Mouwasat Medical Services Co in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.24. Mouwasat Medical Services Co's value of 33.80% is 230.1% above this benchmark. Historically, Mouwasat Medical Services Co's own EBITDA Margin % has ranged from 30.51 to 37.35 over the past decade. While the company's 10-year median is 34.72 vs. the industry median of 10.24, Mouwasat Medical Services Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mouwasat Medical Services Co's current EBITDA Margin % of 33.80% is 230.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mouwasat Medical Services Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mouwasat Medical Services Co's current EBITDA Margin % is 33.80%, which is near median its own 10-year median of 34.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mouwasat Medical Services Co stock overvalued right now?
Based on GuruFocus' analysis, Mouwasat Medical Services Co (SAU:4002) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼109.50, compared to a current price of ﷼60.90 — trading 44.4% below its estimated fair value. The current EBITDA Margin % is 33.80%, which is near median its 10-year median of 34.72 and 230.1% above the Healthcare Providers & Services industry median of 10.24. Mouwasat Medical Services Co's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Mouwasat Medical Services Co (SAU:4002), the current EBITDA Margin % is 33.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mouwasat Medical Services Co (SAU:4002) Overvalued in 2026?
Based on GuruFocus' analysis, Mouwasat Medical Services Co stock appears to be undervalued.
The current stock price of ﷼60.90 is trading 44.4% below its estimated GF Value™ of ﷼109.50.
GuruFocus considers Mouwasat Medical Services Co to be Significantly Undervalued.
Key valuation signals for SAU:4002:
EBITDA Margin %: 33.80% (near median its 10-year median of 34.72)
GF Value™: ﷼109.50 vs. price of ﷼60.90 (44.4% below fair value)
Industry Position: 230.1% above the Healthcare Providers & Services median (#39 of 665)
No single metric tells the full story. See the SAU:4002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mouwasat Medical Services Co is engaged in the acquisition, management, operation, and maintenance of hospitals, medical centers, drug stores, pharmacies, and wholesale of medical equipment and drugs. The company also operates skin care centers that offer clinical and cosmetic dermatology, aesthetic and reconstructive plastic surgery, weight reduction, and esthetician services. It operates in two segments Medical Services segment and Pharmaceuticals out of which the Medical Services segment derives the majority of revenue. The Medical Services segment includes Inpatient and outpatient services. The company provides specialized centers: Eye Center, Robotic Surgeries Center, Diabetes Center, Fertility Unit, Cardiology Center, Stroke Unit, Long Term Care Center, Obesity Center, and others.
100GF Score
Get the complete analysis for SAU:4002
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4002 has been successfully added to your 
